Global Radiopharmaceuticals Market: Report Analyst’s Estimations
Since the first radiopharmaceutical that
was commercialized way back in 1950, Iodine-131 human serum albumin
(RISA), the concept of nuclear medicine has been harnessed consistently
over the past half a century. And, the future of the healthcare industry
substantially depends on radiopharmaceuticals too, for both diagnostic
and therapeutic applications. Radiopharmacology is useful several
branches of medicine including cardiology, nephrology, oncology,
gastroenterology, immunology, and neurology. As per the evaluations of
this business intelligence study, the demand in the global
radiopharmaceuticals market will increment at a steady CAGR of 5.4%
during the forecast period of 2017 to 2024. Revenue-wise, the global
radiopharmaceuticals market is estimated to attain a value of US$7,430.8
million by 2024, mounting from its calculated worth of US$5,145.1
million as of 2017.
The strong prevalence of cancer and
cardiovascular diseases, growing awareness regarding its positive
effects, increasing preference of SPECT and PET scans, and advancements
in radiotracers are some of the key drivers of the radiopharmaceuticals
market. On the other hand, factors such as stringent regulatory
guidelines, supply shortage of radioisotopes, and short half-life of
radiopharmaceuticals are hindering the market from flourishing.
Technetium-99 Identified as Key Radioisotope Segment
On the basis of radioisotope, the
radiopharmaceutical market has been segmented into Gallium-67,
Technetium-99, Rubidium-82, 18F, Iodine-123, Lutetium-177, and
Yttrium-90. Among these, the Technetium-99 segment continues to be the
one with maximum demand, generating a revenue of US$2,582.6 million in
2017. Technetium-99 is the most widely used radioisotope in nuclear
medicine and nearly 70% to 80% of it is being used as a diagnostic
nuclear medicine. Technetium-99 is a short-lived radioisotope (half-life
of 6 hours) when produced from molybdenum-99 inside a nuclear reactor.
On the other hand, the 18F radioisotope
segment of the radiopharmaceutical market has been highlighted as the
one with above-average CAGR of 5.7% during the period of 2017 to 2024.
18F is a positron emitting radioisotope produced in a cyclotron. 18F is
used for positron emission tomography (PET) in order to detect various
types of cancer. Increasing demand for 18F-FDG has advanced
technological development in accelerator technology, radiochemistry,
automated processing modules, detector systems, and imaging software.
Based on source, the nuclear medicine market has been bifurcated into nuclear reactors and cyclotrons. This radiopharmaceutical market report also estimates the potential of demand that can be expected out of the end users of hospitals, diagnostic centers, ambulatory surgical centers, and others such as universities, research laboratories, and pathology laboratories where few clinical trials research programs are enhanced by using nuclear medicines.
The U.S. Radiopharmaceuticals Market to be worth US$3,760.8 million by 2024
Region- and country-wise, this
radiopharmaceuticals market study rates North America as most lucrative,
with the U.S. generating most of the demand. As of 2017, the nuclear
medicine market in North America was estimated to be worth US$3,093.2
million, with the U.S. accounting for 84.4% of the regional demand. This
prosperity of the U.S. pharmaceuticals market can be attributed to
increase in access to health care, rising incidence of cancer and heart
patients, and rapid introduction of advanced technological
implementations in SPECT and PET systems.
On the other hand, the vastly populated
region of Asia Pacific is foreseen to generate demand at a much stronger
CAGR of 6.5% over the course of 2017 to 2024. However, this would
reflect as only the third largest regional demand of pharmaceuticals
worth of US$735.2 million, with Europe sustaining its second position
despite a sluggish growth rate.
GE Healthcare and Siemens Healthineers
have been identified as the leading two companies holding major shares
in the global radiopharmaceuticals market.
No comments:
Post a Comment